Combining Everolimus and EGFR Inhibitors to Overcome Drug Resistance in Cancer
Author Information
Author(s): Bianco R, Garofalo S, Rosa R, Damiano V, Gelardi T, Daniele G, Marciano R, Ciardiello F, Tortora G
Primary Institution: Università di Napoli Federico II
Hypothesis
Can mTOR inhibition with everolimus restore sensitivity to EGFR inhibitors in resistant tumors?
Conclusion
The combination of everolimus and EGFR inhibitors significantly inhibits tumor growth and overcomes resistance in cancer cell lines.
Supporting Evidence
- Everolimus was effective in cancer cell lines resistant to EGFR inhibitors.
- The combination of everolimus and gefitinib resulted in over 90% tumor growth inhibition in xenografts.
- Everolimus reduced VEGF secretion in both sensitive and resistant cancer cells.
- Combination treatment improved survival rates in mice with resistant tumors.
Takeaway
This study shows that a drug called everolimus can help other cancer drugs work better, especially in cases where the cancer has become resistant to those drugs.
Methodology
The study used human cancer cell lines and xenografts to test the effects of everolimus alone and in combination with EGFR inhibitors gefitinib and cetuximab.
Statistical Information
P-Value
<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website